Replies to post #485283 on Anavex Life Sciences Corp (AVXL)

[rx7171]

This is true.
All treated patient AD symptoms will progress.
The rate of progress is slowed, in the case of the 70-80% of those with the wild type sigma-1 slowed on average 49.8% which is a huge improvement not a cure. Adding years of cognitive and functional independence.

What we need to find out is what happens when Blarcamasine is administered prior to any overt symptoms of AD appear.
Delaying even the onset of symptoms 5-10 years would be huge, possibly delaying them into an advanced age when other ailments become terminal.

However that could also be pushed far into the future since the action of Blarcamasine on Sigma-1 in multiple critical organs has the potential to slow their biological aging.

[Investor2014]

From Anavex and people here claiming that failing the ADL co-primary endpoint is irrelevant in MCI patients, Anavex now taunts an ADL win in the OLE comparing late and early starters.

At the same time we see from the P2b/3 baseline data that most patients were stage 3 or 4 already and those that were MCI must have quickly progressed to mild AD, because otherwise ADL would not be a reliable measure in the OLE.

It does smell a bit of selective reporting by Anavex, but hopefully the upcoming OLE data presentation will clarify the method and data used to reach the abstract conclusions that we have seen.

EMA will be digging into the data, not just disregarding the failed ADL endpoint without scrutiny. Soon we should be in the clock stop one zone and how long that will be will tell a story - hopefully the clock will start ticking again around the median 81 days…and hopefully the OLE data reveal will bring clarity